MedPath

CXA-10

Generic Name
CXA-10
Drug Type
Small Molecule
Chemical Formula
C18H33NO4
CAS Number
875685-46-4
Unique Ingredient Identifier
1N19AGY57Y

Overview

CXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: Oct 17, 2025

CXA-10 (10-Nitrooleic Acid): A Comprehensive Pharmacological and Developmental Review of a Novel Endogenous Signaling Modulator

Executive Summary

CXA-10, known chemically as 10-Nitrooleic acid, is an investigational small molecule drug belonging to the class of nitro fatty acids (NFAs). It is an endogenous signaling molecule formed in the body under conditions of inflammation and nitrative stress.[1] The therapeutic rationale for CXA-10 was built upon a compelling and pleiotropic mechanism of action, positioning it as a potential treatment for a range of complex diseases characterized by oxidative stress, inflammation, and fibrosis.[3]

The primary mechanism of CXA-10 involves its function as an electrophilic signaling mediator. It modulates multiple fundamental cellular pathways, most notably through the potent activation of the cytoprotective Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway and the concurrent inhibition of the pro-inflammatory Nuclear Factor-kappa B (NF-κB) signaling cascade.[2] This dual action, which simultaneously enhances endogenous defense mechanisms while suppressing inflammatory damage, was supported by a robust body of preclinical evidence across various animal models of renal, cardiopulmonary, and metabolic diseases.

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.